Compounds and methods for selective proteolysis of glucocorticoid receptors

Abstract

The present disclosure relates to steroidal glucocorticoid receptor (GR) ligands and related compositions that degrade the GR and/or modulate its activity that may be utilized as pharmaceuticals for the treatment of diseases including cancer.